Novartis launches new cell and gene therapy at Dubai’s 2020 Expo

UAE- Novartis, a Swiss pharmaceutical multinational that is currently involved in cell and gene therapy innovation, has been able to assist five young patients from the UAE who were facing the threat of progressive blindness. Dr Ahmed Baly, chief scientific officer at Novartis Gulf, during a presentation on cutting-edge cell and gene therapy innovations titled ‘Remaining Medicine’ at Expo 2020 Dubai said: “These five young individuals would have suffered progressive loss of sight. Our one-time treatment based on cell and gene therapy was successfully able to prevent further deterioration of…

Read More

Genentech’s new continuous release eye treatment gains FDA approval

USA – The FDA has approved ranibizumab 100 mg/mL injection for wet age-related macular degeneration in patients who have previously responded to at least two anti-VEGF injections, according to Genentech. The new therapy (Susvimo), formerly known as the Port Delivery System (PDS) with ranibizumab, is designed for intravitreal use via ocular implant for the treatment of people with wet, or neovascular, Age-Related Macular Degeneration (AMD). This is the only FDA-approved wet AMD therapy that allows for as few as two treatments per year. The availability of Susvimo will decrease the…

Read More

Remote glaucoma care Implandata voted among top 12 techpreneurs

GERMANY – Implandata Ophthalmic Products, a digital health eye care company, has been named a top 12 health techpreneur at the Medica Healthcare Innovation World Cup, the world’s largest medical trade fair. Implandata was named a leading breakthrough health care innovator among more than 300 competitors and has been invited to present its disruptive Eyemate solution at the Medica Connected Health Care Forum on November 15th, 2021. Earlier in 2021, the US FDA granted Breakthrough Device Designation. The system allows patients to self-measure critical disease parameters and then automatically sends…

Read More

New targets for glaucoma treatment identified in mice models-Study

USA – A Northwestern Medicine study’s findings could lead to an effective glaucoma treatment, which would be a significant step forward in the fight against the condition. The Northwestern University Fienberg School of Medicine researchers used mouse models to identify novel glaucoma treatment targets, such as preventing a severe pediatric form of the condition. The groundbreaking study also discovered a potential new class of glaucoma treatment for the most common form of the disease in adults. The findings are published in the journal Nature Communications in a paper titled, “Cellular…

Read More

UCB to license its AI technology for fracture identification to ImageBiopsy Lab

BELGIUM – UCB has announced a strategic out-licensing of its AI-based fracture identification technology, BoneBot, to ImageBiopsy Lab, for further development and bring it to clinical practice by 2023. The radiology AI solution will screen CT scans for “silent” or asymptomatic fractures in the spine, which would otherwise go unnoticed and unreported. The BoneBot digital health tool uses machine learning to detect silent or asymptomatic fractures in the spine’s vertebrae, a feature of the bone-wasting disease osteoporosis that can go undetected in more than two-thirds of cases. Catching these fractures…

Read More

Hyloris announces approval of novel drug for post-operation pain management

BELGIUM – Hyloris Pharmaceuticals SA, a specialty biopharmaceutical company dedicated to addressing unmet medical needs by reinventing existing medications, has announced the expansion of the European footprint of Maxigesic IV to treat post-operative pain in the UK. Hyloris Pharmaceuticals has a diverse pipeline of 13 reformulated and repurposed value-added medicines that have the potential to outperform existing medications. In addition, the company is developing and registering three high barrier generic products. Two products are currently in the early stages of commercialization with partners: Sotalol IV for atrial fibrillation treatment and…

Read More

First US hospital installs Siemens Healthineers’ new imaging technology

USA – New York-based Long Island Jewish Valley Stream has become the first healthcare institution in the United States to install the LUMINOS Lotus Max, a premium 2-in-1 remote-controlled imaging system from Siemens Healthineers. The new imaging technology delivers enhanced patient care and streamlines the diagnostic imaging process with better outcomes for patients. The LUMINOS Lotus Max is a remote-controlled, two-in-one fluoroscopy and radiography imaging system that allows medical staff to perform two previously separate imaging tests with one machine and quickly switch between them in a truly integrative manner.…

Read More

Roche ties up with Ibex Medical Analytics to develop AI-based cancer detection

SWITZERLAND – Roche has announced a collaboration with Ibex Medical Analytics, an Israeli artificial intelligence-based cancer diagnostics startup to develop artificial intelligence assisted cancer detection device to help diagnose early cancer detection. The companies will collaborate to create an embedded image analysis workflow for pathologists to use the cloud version of Roche’s uPath enterprise software to access Ibex’s AI algorithms, insights, and decision support tools. The US Food and Drug Administration recently granted Breakthrough Device Designation to Ibex’s Galen platform, which is CE marked in Europe for breast and prostate…

Read More

FDA OK’s Roche novel therapy for non-small cell lung cancer

SWITZERLAND – Roche, a global pioneer in pharmaceuticals and diagnostics has announced that The FDA has approved Tecentriq as adjuvant treatment after surgery and platinum-based chemotherapy for adults with Stage II-IIIA non-small cell lung cancer. The approval was based on preliminary findings from the Phase III IMpower010 study. Following surgery and platinum-based chemotherapy, treatment with Tecentriq, or atezolizumab, reduced the risk of disease recurrence or death by 34 percent in people with Stage II-IIIA non-small cell lung cancer, compared to best supportive care. Tecentriq has previously demonstrated clinically significant benefit…

Read More

Philips’ IntelliSite pathology suite to bode well for digital pathology diagnostics

NETHERLANDS – Royal Philips, a global leader in health technology has announced the launch of its next-generation digital pathology solution, putting digital pathology at the heart of enterprise-wide healthcare informatics. The Philips Digital Pathology Suite – IntelliSite – is a comprehensive, scalable suite of software tools and capabilities designed to help streamline workflows, improve diagnostic confidence, facilitate team collaboration, integrate artificial intelligence (AI), and increase pathology lab efficiency. Philip’s IntelliSite Pathology Suite (PIPS) is the first FDA-approved digital pathology system in the market. According to Fortune Business Insights, Philips’ Intellisite…

Read More